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Abstract
Pilocarpine-induced seizures in rats provide a widely animal model of temporal lobe epilepsy. Some evidences reported in the
literature suggest that at least 1 h of status epilepticus (SE) is required to produce subsequent chronic phase, due to the SE-
related acute neuronal damage. However, recent data seems to indicate that neuro-inflammation plays a crucial role in
epileptogenesis, modulating secondarily a neuronal insult. For this reason, we decided to test the following hypotheses: a)
whether pilocarpine-injected rats that did not develop SE can exhibit long-term chronic spontaneous recurrent seizures (SRS)
and b) whether acute neurodegeneration is mandatory to obtain chronic epilepsy. Therefore, we compared animals injected
with the same dose of pilocarpine that developed or did not SE, and saline treated rats. We used telemetric acquisition of EEG
as long-term monitoring system to evaluate the occurrence of seizures in non-SE pilocarpineinjected animals. Furthermore,
histology and MRI analysis were applied in order to detect neuronal injury and neuropathological signs. Our observations
indicate that non-SE rats exhibit SRS almost 8 (+/22) months after pilocarpine-injection, independently to the absence of initial
acute neuronal injury. This is the first time reported that pilocarpine injected rats without developing SE, can experience SRS
after a long latency period resembling human pathology. Thus, we strongly emphasize the important meaning of including
these animals to model human epileptogenesis in pilocarpine induced epilepsy.
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Introduction
Temporal lobe epilepsy (TLE) is the most common epileptic
syndrome in adult humans (see, for review, [1]); for this reason, the
neurobiological bases of TLE have been extensively studied in
preclinical research (see, i.a., [1,2]), and adequate animal models
paralleling human pathology are required. TLE refers to a chronic
condition characterized by seizures primarily involving the
temporal lobe, despite of the fact that other structures, such as
the neocortex, may be the origin of the seizures [3]. In rodents,
systemic administration of single dose of pilocarpine, a muscarinic
cholinergic agonist, lead to status epilepticus (SE) and, after a seizure-
free period, to a chronic condition determined by spontaneous
recurrent seizures (SRS). Pilocarpine has been recently used also to
model pharmacoresistance in TLE [4].
Initially, this model has been proposed as sufficiently isomorphic
with the human disease [5], but several aspects seem to differ
significantly, at least concerning the extent of damage and the
incidence of SE, as well as the inflammatory origin [6]. In fact, 2/3
of human patients suffering TLE presents hippocampal sclerosis,
whereas the remaining 1/3 presents focal limbic lesions. This latter
group does not exhibit pronounced segmental neuronal cell loss or
concomitant sclerosis [7]. On the other hand, massive SE-induced
neurodegeneration in different brain areas has been reported in
pilo-treated animals [8], as well as in other post-SE models of TLE
(e.g., kainic acid [9–11]). The pattern of the damaged structures is
similar in both models, but with different temporal profile of brain
injury [9].
It is interesting to note that systemic administration of
convulsant dose of pilocarpine (.320 mg/Kg) does not elicit SE
in all injected animals [9,12]. These animals are often repeatedly
injected until SE-onset [13,14] or used as control group [15,16],
whereas no studies are available on possible long-term EEG effects
induced by pilocarpine on these animals. Despite of the possible
relevance to the human pathology, very few experimental works
have focused their attention to this phenomenon, and results seem
contrasting. De Mello and colleagues (2005) reported that
pilocarpine-injected animals without developing SE are preserved
from age-related memory and cognitive impairment [17].
This study is aimed to assess: a) whether pilocarpine-injected
rats that did not develop SE may exhibit long-term chronic SRS;
b) pathological alterations in different time-points in the two
experimental groups (SE versus no-SE pilo-injected rats) using
structural and functional MRI; c) neuropathological evidences
studied by the mean of an accurate stereological study. Therefore,
we planned a comparison between animals injected with the same
dose of pilocarpine that developed or did not SE, and saline
treated rats (Fig. 1).
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Seizure detection
The occurrence of seizures was evaluated during the first five
working days of each month per 12 months. As expected, control
rats did not show any seizure during all the evaluated registration
time, and on the other hand, since the first evaluation, pilocarpine-
treated animals that develop SE (PILOSE animals) developed SRS
that were always present until the end of the registration. On the
contrary, surprising findings were evidenced in pilocarpine-treated
animals that did not develop SE (PILOnoSE animals), in which
SRS occurred after eight months (+/22 months) of monitoring
EEG and persisted during the whole registration less frequently
(0.5–1 seizures/week) than the cyclical pattern observed in
PILOSE animals (4–6 seizures/week).
MRI data
T2-weighted (T2-w) signal changes were also consistently
observed in the epileptic animals (24 h PILOSE, 1 year PILOSE
and 1 year PILOnoSE groups; Fig. 2). Hyperintense areas were
identified in the neocortex, rhinal and piriform cortices, as well as
in the hippocampus and anteromedial thalamus. T2-w images
analysis clearly showed a similar pattern of changes in the epileptic
rats, highlighting the signal increase throughout the cortex,
hippocampus and thalamus over other brain structures (Figs. 2–
3). Particularly, we found a significant increase of the signal in
somatosensory and piriform cortices of PILOSE animals compare
to both, control and PILOnoSE (p,0.001) 24 h after pilocarpine
injection, and the same differences but less noted (p,0.05) were
observed in hippocampus at the same time point (24h). But the
most interesting result was observed in medial thalamic nuclei,
where, although at 24 h the signal was significantly increased
(p,0.001) in PILOSE animals with regard to the control and
PILOnoSE ones, it appeared an opposite signal increasing when
evaluating 1 year later the same groups, being highly significant
the increase of the signal in the PILOnoSE group compare to the
control (p,0.01) and PILOSE group (p,0.001).
Regarding rCBV evaluation, we observed interesting findings in
cerebral cortex and thalamus (Fig. 2; Fig. 4). Less marked
differences were found in hippocampus. Specifically, only the
24 hours study provides statistically significant results except for
the inferior layers of the somatosensory cortex where rCBV value
was significantly increased (p,0.05) in PILOSE and PILOnoSE
animals compare to control ones after 1 year of follow up (Fig. 4).
Thus, after 24 h of the pilocarpine/saline injection, the increase of
the value was highly significant in superficial layers of the
somatosensory cortex for both, PILOSE and PILOnoSE animals
(p,0.001) compare to control ones, being at the same time equally
significant the increase of the value for PILOSE animals (p,0.001)
respect to PILOnoSE animals. Also in medial thalamus we found
significance (p,0.001) for PILOSE and PILOnoSE animals
compare to control animals and, in hippocampus only PILOSE
animals showed higher values (p,0.05) respect the others. It is
clear that rCBV results thus in a more predictive and sensible
method to detect and forecast future structural and functional
alterations that will appear only many months later. Furthermore,
these data indicate that PILOnoSE animals do not show any
structural alterations during the acute phase, whereas vascular
alterations are more precocious.
Histopathological data
Histopathological data were analyzed and compared with MRI
data. In Nissl-stained sections, tissue and cell changes in
pilocarpine injected animals brains exhibited a closed topograph-
ical correspondence with the areas of T2W hyperintensity (Figs. 2–
3). In the cerebral cortex of PILOSE animals, edematous
Figure 1. Schematic representation of the experimental design relative to all the different conditions and techniques performed.
doi:10.1371/journal.pone.0005759.g001
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pilocarpine injection (Fig. 2). In the acute phase (24 h after SE-
onset) pyramidal neurons appeared shrunken with a fusiform
shape showing a typical picnotic conformation (Fig. 2). Rarefac-
tion of neurons and dilated intercellular spaces were also detected
in the hippocampus. In PILOnoSE animals non significant
alterations have been observed both quantitatively and qualita-
tively, with no evident signs of neuronal suffering or degeneration.
Discussion
We hereby report for the first time that animals injected with
pilocarpine that did not exhibit SE acutely (PILOnoSE) developed
late-onset SRS many months after pilo injection. Differently to
PILOSE animals, SRS can be unrelated to previous acute MRI
detectable cellular or tissue damage. However, perfusion MRI
demonstrated to be highly sensible to vascular alterations ongoing
in the first 24 h after pilocarpine injection. In fact, even in absence
of a clear structural degeneration, an augmented cerebral blood
volume in cortical and limbic areas of PILOnoSE animals has been
detected. In addition, we reported evidences that cortico-thalamic
domains can be deeply involved in the pathogenesis of pilocarpine-
induced epilepsy.
Our data cofirm previous evidences, that long-term neuronal
consequences of high-dose cholinergic activation are not necessarily
derived from prolonged seizure activation (as seen in SE) [18].
The present data disconfirm that an initial neurodegeneration is
the responsible for epileptogenesis in the pilocarpine model.
However, there is a wealth of data indicating that SE, with a
minimal duration of 30–60 min is required for epileptogenesis
[19,20]; consequently, SRS has mainly been considered as
functional response of the abnormal neuronal circuitry subsequent
to post-SE brain damage [19,20]. The necessity of SE in order to
establish chronic SRS is a crucial point in the evaluation of the
relevance of this experimental model to the human pathology. As
recently reported, translation of experimental SE data to the clinical
situation should be made with caution [21]. Status epilepticus in
animal models has different pathological features in relation to
human condition, and the extent of neuronal damage is likely to be
overestimated in experimental studies [21]. We should reason that,
whereas in pilocarpine model all animals (100%) that develop SE
will experience chronic SRS, in humans SE does not necessarily
carry an increased risk of consequent chronic epilepsy [22]. In fact,
the risk of epilepsy following acute symptomatic SE was reported by
Hesdorfferetal.[23] tobelessthan K(42%ofcases), 10yearslater.
These data suggest that, differently from the animal models, in
human patient SE cannot be considered a sufficient condition for
epileptogenesis. However, there is substantial evidence in humans
indicating that the presence of additional risk factors can contribute
to greater chance of developing epilepsy in case of more diffuse
damage [24,25]
Concerning MRI, it is interesting that similar T2-w signals were
observed between early stages (24 h) of epileptogenesis in PILOSE
and long-term (1 year) effects of PILOnoSE animals. T2-w increase
is usually associated to an increase in interstitial water associated
with the development of vasogenic edema (see, as review, [26]);
such alteration can be detected several weeks after the initial insult
[27]. Seizure-induced neurodegeneration in the medial thalamus
has been linked to short- and long-term consequences, such as
chronic SRS [28]. The fact that PILOnoSE show MD alterations
Figure 2. MRI (T2 and rCBV) and histological (low-power vs higher magnifications) data are presented. The three histological areas used
for the cell density evaluation reported above are, respectively, cerebral cortex, pyramidal layer of CA1 and hilus of the dentate gyrus.
doi:10.1371/journal.pone.0005759.g002
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suggest that the epileptogenic mechanisms in these animals can be
similar to PILOSE, but extended for a longer period. It is
interesting to note that other brain areas of PILOnoSE rats do not
show any significant T2-w alterations, pointing out a crucial role of
the thalamus. To this regard, evidence in literature suggest that the
high metabolic activity detected in this region after 24 h of
pilocarpine administration may reflect a sustained increase in
inhibitory activity for seizure control, taking part in the chronic
epileptic phenomena [29]. Furthermore, the observed cell loss
after 1 year in PILOnose would be coherent with the destruction of
a structure involved in seizure inhibition [30].
Regional perfusion levels provide critical information on the
development of tissue damage [26]. Perfusion-weighted technique
has been applied to the study of experimental epilepsy (see, i.a.,
[31,32]), indicating a crucial role of vascular alterations in the
pathophysiology of pilocarpine-induced epilepsy. Parametrical
rCBV maps supply quantitative information on physiological
and/or pathological blood volume, providing thus a functional
parameter that can be also independent to structural lesions.
Figure 3. Bar graphs for T2 ratio in different brain areas. T2 ratio was calculated dividing T2 values for each region of interest (ROI) for the
baseline (muscle levels). Data were evaluated with one-way analysis of variance (ANOVA), following LSD post-hoc test, setting the significance at p,.05.
doi:10.1371/journal.pone.0005759.g003
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pilocarpine on the endothelial cells. It is interesting to note that
vascular alterations, and in particular leukocytes recruitment, have
been recently reported to play a key role for epileptogenesis [6].
Furthermore, recent works demonstrated a direct effect of
pilocarpine on endothelial cells [33,34]. In particular, it has been
demonstrated that seizure-like activity was obtained in vivo only in
case of blood brain barrier (BBB) leakage. Furthermore, Marchi
and collaborators reported that focal BBB leakage and increased
serum levels of IL-1 b occur in vivo after pilocarpine injection
Figure 4. Bar graphs for rCBV values in the same brain areas that were identified for T2 analysis.
doi:10.1371/journal.pone.0005759.g004
SRSs Do Not Require SE
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5759prior to the development of SE and despite of methyl-scopolamine
pretreatment [33]. These evidences, all together, point out a
peripheral action of systemic pilocarpine injection when inducing
epilepsy and could explain the vascular alterations found after
24 hours of the pilocarpine injections in PILOnoSE rats.
Our histopathological data are in agreement with Scharfman
and collaborators [12]. These Authors used PILOnoSE animals for
slice experiments from approximately 1 to 7 months after
pilocarpine administration, finding in K of the animals a small
degree of cell loss in the entorhinal cortex, as well as, in one
animal, mossy fiber sprouting, usually observed in PILOSE animals
during latent period [12].
Regarding the absence of neuronal damage in PILOnoSE
animals after 24 h of the pilo injection, it would be important to
take in account that juvenile rats experiencing SE show no cell
death and no recurrent seizures. Whereas, in older rats, the
experienced seizures and the acute inflammatory reaction suffered
would become chronic and excessive, as reflected by the microglial
activation in hippocampus and would be accompanied by seizure-
induced cell death and development of SRS [35]. In addition,
Brandt and collaborators demonstrated that effective neuropro-
tection (blockade of cell death) after SE did not prevent the
development of SRS in adul rats. This report evidences the
distinction and the different contribution in epileptogenesis of two
processes, inflammation and neuronal death, that could not be
consequent, but subsequent processes [36].
We should also consider that animals that not evolve to SE after
pilocarpine injection may have a ‘‘natural’’ lower sensitive for
seizures (higher threshold), justifying the long-term epileptogenic
required time and their lower frequency of SRS (when compared
to PILOSE); it becomes thus important to identify the individual
susceptibility to electrical alterations in new experiments.
Concluding, in this experiment we have evidences for the first
time, that pilocarpine injected rats without developing SE, can
experience SRS after a long latency period resembling human
pathology. For these reasons, we strong emphasize the importance
of including these animals in the study of epileptogenesis modeling
human epilepsy. It remains unclear how other mechanisms can
contribute to the appearance of chronic seizures in the pilocarpine
model, and further investigations are required.
Materials and Methods
We used 2-moths-old male adult Wistar rats weighing 250–
300 g. kept under controlled environmental parameters (temper-
ature 2363.0uC, humidity 50–60% and 12 h inverted light-dark
cycles) and veterinarian control. The experiments were conducted
following the principles of the NIH Guide for the Use and Care of
Laboratory Animals, and the European Community Council (86/
609/EEC) directive.
Animals were injected with methyl-scopolamine (Sigma, 1 mg/
kg, i.p) 30 min prior pilocarpine injection (Sigma, 380 mg/kg, i.p)
to minimize peripheral cholinergic effects. Control rats received
saline instead of pilocarpine. Immediately, rats were video recorded
for 24 hours and during this time, or until 15 days after, depending
on the SE occurrence, pilocarpine injected animals were subdivided
in SE (PILOSE) or non-SE (PILOnoSE) groups (see [10]). Four hours
after pilocarpine/saline injection, all animals received diazepam
administration (single 4 mg/kg i.p. injection) in order to standardize
the duration of seizure activity in SE animals. In all groups, the time
points investigated were 24 h and 1 year after pilocarpine/saline
injection to correlate short and long-term effects.
The experimental design has been summarized in Fig. 1. Two
animals belonged to each group were followed up for 12 months
by telemetry system as previous studies [5]. After two weeks of the
pilocarpine/saline injection, animals were implanted i.p. with the
telemetry transmitter TA11CTA-F40 (Data Science International,
Arden Hills, MN, U.S.A) for cortical sub-dural above the parietal
cortex. EEG recording, locomotor activity and temperature
monitoring. These devices continuously sense, process and
transmit information from the animal to a data storing system.
Prior to the surgery all animals received medetomidine (Dormi-
torH 0.05 mg/kg s.c) as sedative 5 min before the anesthetic
tiletamina+zolacepam (ZoletilH 20 mg/kg i.p), then the analgesic
carprofen (RimadylH 5 mg/kg s.c), and amoxicilina (ClamoxylH
LA 150 mg/kg s.c) as prophylactic antibiotic. The same dose of
the antibiotic was given the day after the surgery. Animals were
allowed to recover for one week after surgery. Four equivalent
non-implanted rats per group were subjected to MRI technique
and Nissl staining to detect morphological features correlated to
the data monitoring (Fig. 1).
In the acute study (24 h after pilocarpine-injection), MRI and
histological techniques were used to describe neurophatological
signs in the groups analyzed. Hyperventilation was observed
during SE but ended after its arrest, and all animals exhibited
normal spontaneous breathing at the time of MRI analysis. MRI
technique has been widely used in studies of experimental epilepsy.
MRI experiments were performed using a Bruker Biospec
Tomograph equipped with an Oxford, 33-cm-bore, horizontal
magnet operating at 4.7T. The data are analyzed with T2W
RARE sequences. Animals were anesthetized with 1% halothane
in 1 L of oxygen in air per minute (initial dose: 4% halothane);
rectal temperature and heart rate were monitored and were
similar in control, PILOSE and PILOnoSE animals.
Regional cerebral blood volume (rCBV) mapping was carried
out using the same Biospec system used structural MRI analysis. In
these animals, anesthetized as indicated above, the tail vein was
catheterized for contrast medium administration. SineremH,a n
ultra small particle iron oxide (USPIO) contrast agent (kindly
supplied by Guerbet, Aulnay-Sous-Bois, France) was used.
SineremH has an iron-oxide core of about 6 nm diameter coated
by dextran (coated particle dimensions of about 20 nm) and is
characterized by a blood half-time longer than 2 h in rats [12].
SineremH was dissolved in saline and injected at a 6 mg/kg dose
(mg are referred to iron) and images were acquired with gradient-
echo sequence before and after USPIO administration.
At the end of MRI analysis, the anesthesia was implemented
with barbiturates (Tionembutal, 50 mg/kg, ip) and the rats were
perfused via the ascending aorta with PBS followed by 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (PB). Brains
were then removed from the skull, left in 30% sucrose overnight
and coronal cut (40 mm thickness) on a freezing microtome
(Reichert-Jung, Vienna, Austria). All sections were collected,
divided in 3 adjacent series and mounted on 2% gelatin-coated
slides. The first series were Nissl-stained, dehydrated, and cover
slipped. Nissl-stained sections were examined under a microscope
under bright-field illumination. The rat atlas of Swanson (1992)
was used to match in all animals the same levels of sections
selected for further analysis [11].
Histological data (neuronal density) and MRI data (T2W and
rCBV values) obtained in the three experimental groups, were
analyzed with one-way analysis of variance (ANOVA), followed by
the LSD post hoc test, setting the significance at P,0.05.
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